Abstract
BackgroundThis study aims to investigate galectin-1 (Gal-1) expression in the serum and placenta of pregnant women with fetal growth restriction (FGR) and its significance.MethodsThirty-one pregnant women with single-birth FGR but without comorbidities, eight pregnant women with FGR and preeclampsia (PE), and eight pregnant women with FGR and gestational diabetes mellitus (GDM) were enrolled as the study group, while 20 pregnant women with normal singleton pregnancy in the same period were enrolled as the control group. The serum Gal-1 level was detected using an enzyme-linked immunosorbent assay (ELISA), and Gal-1 expression in the placenta was detected by western blot.ResultsThe results revealed that, compared with the control group, the serum Gal-1 level decreased in the women with FGR without comorbidities, and the difference was statistically significant (P < 0.001). Compared with the control group, the difference in serum Gal-1 expression in the FGR-PE group was not statistically significant (P = 0.29). The peripheral serum Gal-1 level decreased in the FGR-GDM group compared with the control group, and the difference was statistically significant (P < 0.001). The serum Gal-1 level was positively correlated with birth weight (r2 = 0.172, P < 0.01). Compared with the control group, the Gal-1 expression level decreased in the placenta of the pregnant women with FGR without comorbidities (P < 0.05).ConclusionsGal-1 exhibits low expression in the serum and placenta of pregnant women with FGR. In addition, Gal-1 may be involved in the pathogenesis of FGR and could represent a new diagnostic marker of the disease.
Highlights
This study aims to investigate galectin-1 (Gal-1) expression in the serum and placenta of pregnant women with fetal growth restriction (FGR) and its significance
Study subjects In the present study, 31 pregnant women with singlebirth FGR but without comorbidities, eight pregnant women with FGR and preeclampsia (PE), and eight pregnant women with FGR and gestational diabetes mellitus (GDM) admitted to the Taizhou Hospital of Zhejiang Province from January 2017 to February 2019 were enrolled as the study group
General situations In the present study, 31 pregnant women with singlebirth FGR without comorbidities, eight pregnant women with preeclampsia (PE) and FGR, and eight pregnant women with FGR and gestational diabetes mellitus (GDM) admitted to the Taizhou hospital, Zhejiang Province from January 2017 to February 2019 were enrolled as the study group
Summary
This study aims to investigate galectin-1 (Gal-1) expression in the serum and placenta of pregnant women with fetal growth restriction (FGR) and its significance. Fetal growth restriction (FGR) refers to the failure of a fetus to reach its growth potential in the uterus due to various factors. It is a common complication during the perinatal period [1]. Galectin is involved in regulating maternal-fetal immune tolerance and promoting angiogenesis in placenta formation; as. Previous studies have shown that Gal-1 participates in the regulation of the biological behavior of trophoblasts and angiogenesis and in the establishment of the microenvironment of maternal-fetal immune tolerance at the maternal-fetal interface [8, 9]. Few studies have examined the role of Gal-1 in FGR
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have